Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing next-generation precision medicines targeting FGFR biology. The news flow around TYRA, as reflected in its recent press releases, centers on clinical trial progress, scientific presentations, regulatory designations and corporate developments related to its FGFR-focused pipeline.
Investors and followers of TYRA news can expect updates on dabogratinib (formerly TYRA-300), the company’s lead oral FGFR3-selective inhibitor. Recent announcements include dosing the first patient in the SURF302 Phase 2 study for FGFR3-altered intermediate risk non-muscle invasive bladder cancer, dosing the first child in the BEACH301 Phase 2 study for pediatric achondroplasia, and plans to expand development into low-grade upper tract urothelial carcinoma through the SURF303 study. Tyra also reports interim proof-of-concept results in metastatic urothelial carcinoma and regulatory designations such as Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in achondroplasia.
News coverage further highlights progress in early-stage oncology programs TYRA-200 and TYRA-430, including enrollment and dosing in the SURF201 and SURF431 Phase 1 studies for intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven tumors. Tyra’s communications also describe scientific visibility events, such as a late-breaking poster on TYRA-300 preclinical data at ENDO 2025 and fireside chats or presentations at healthcare and biotechnology investor conferences.
In addition, Tyra Biosciences issues quarterly financial results press releases and Form 8-K filings that summarize research and development spending, cash runway expectations and key clinical milestones. Corporate news has included strengthening the leadership team with appointments in operations and regulatory affairs. For readers tracking TYRA, this news stream provides ongoing insight into the company’s clinical development timelines, scientific activities and corporate priorities in FGFR-targeted precision medicine.
Tyra Biosciences (Nasdaq: TYRA) reported Q4 and full‑year 2025 results and outlined its "dabogratinib 3x3" strategy targeting LG‑UTUC, IR NMIBC and achondroplasia. TYRA holds $256.0 million in cash and marketable securities, with a stated runway through at least 2027. Key near‑term clinical catalysts: SURF302 interim data by end 1H 2026 and BEACH301 safety sentinel results in 2H 2026; SURF303 first patient expected in 2026. Full‑year R&D rose to $102.9M and net loss widened to $119.9M.
Tyra Biosciences (NASDAQ: TYRA) announced two poster presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium, held February 26-28, 2026 in San Francisco.
Posters on dabogratinib (formerly TYRA-300) include ctDNA monitoring in metastatic urothelial cancer (Abstract 809) and a SURF302 Phase 2 trial in non-muscle invasive bladder cancer (TPS886), both presented February 27, 2026 at 11:30 AM–12:45 PM PST. Posters will be posted on TYRA's investor relations website after the presentations.
Tyra Biosciences (Nasdaq: TYRA) will participate in multiple investor conferences between Feb 26 and Mar 12, 2026, including virtual and in-person presentations and one-on-one meetings.
Key events: Oppenheimer Life Sciences (virtual chat) on Feb 26, 2026; TD Cowen (hybrid) on Mar 4, 2026 in Boston; and multiple Miami conferences March 8–12 with webcasts and replays available on the company's investor site.
Armada Hoffler (NYSE: AHH) will report fourth quarter results for the period ending December 31, 2025, and provide projected guidance for 2026 on Monday, February 16, 2026 at ~4:00 PM ET.
Management will host a conference call and webcast on Tuesday, February 17, 2026 at 8:30 AM ET to discuss earnings, guidance, and related information. Dial-in numbers: (+1) 800 549 8228 (toll-free) or (+1) 646 564 2877; conference ID 89782. The call will be available on the company investors page at ArmadaHoffler.com.
A telephonic replay will be available through Thursday, March 19, 2026 via (+1) 888 660 6264 or (+1) 646 517 3975 with passcode 89782. A webcast replay will be accessible for 30 days beginning ~two hours after the call.
Tyra Biosciences (Nasdaq: TYRA) appointed Bhavesh Ashar as Chief Operating Officer (effective immediately) and Heather Faulds as Chief Regulatory Officer (effective December 8, 2025).
Both hires bring senior pharmaceutical experience: Mr. Ashar has 25+ years including chief commercial roles and launches of OGSIVEO and GOMEKLI; Ms. Faulds has 20+ years leading global regulatory strategy and was involved in approvals including SPINRAZA and LYBALVI. They will support advancement of oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparation for potential Phase 3 programs.
Tyra Biosciences (Nasdaq: TYRA) announced management will participate in investor events in November–December 2025, including a hybrid presentation at the Jefferies London Healthcare Conference and one-on-one meetings at the 37th Annual Piper Healthcare Conference.
Jefferies presentation: Wednesday, November 19, 2025 at 4:00 PM GMT (hybrid slides & moderated Q&A) in London, UK; a live webcast will be available on Tyra Biosciences' For Investors page and replayed after the event. Piper conference meetings: December 2–4, 2025 in New York, NY.
Tyra Biosciences (Nasdaq: TYRA) reported Q3 2025 results and clinical progress on November 5, 2025. Key clinical updates: TYRA dosed first patients with dabogratinib in BEACH301 (achondroplasia) and SURF302 (FGFR3-altered IR NMIBC), advanced development into LG-UTUC with an IND cleared by the FDA, and expects interim Phase 2 readouts in 2026.
Financials: TYRA held $274.9 million in cash, cash equivalents and marketable securities as of September 30, 2025, providing runway through at least 2027. Q3 R&D was $25.5M, G&A $7.5M, and net loss $29.9M.
Tyra Biosciences (Nasdaq: TYRA) has announced a significant milestone in its BEACH301 Phase 2 clinical study, with the first child being dosed with dabogratinib (TYRA-300) for treating achondroplasia, the most common form of dwarfism.
Dabogratinib is positioned as the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, which affects approximately 250,000 individuals worldwide. The drug targets the FGFR3 G380R mutation, present in 99% of achondroplasia cases. Initial results from the safety sentinel cohort are expected in 2H 2026.
The study aims to evaluate the safety and efficacy of this once-daily oral treatment, developed using TYRA's proprietary SNÅP platform, offering a potentially more accessible treatment option for children with achondroplasia.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.
The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.
Webcasts of both events will be accessible through Tyra's investor relations website.
Tyra Biosciences (NASDAQ: TYRA) reported Q2 2025 financial results and significant progress in its clinical programs. The company maintains a strong financial position with $296.3 million in cash and equivalents, providing runway through 2027. Key developments include dosing the first patient in SURF302, a Phase 2 study evaluating dabogratinib for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
The company reported a net loss of $28.1 million for Q2 2025, with R&D expenses of $24.3 million and G&A expenses of $7.1 million. TYRA is advancing multiple clinical programs, including BEACH301 for achondroplasia, SURF431 for hepatocellular carcinoma, and SURF201 for intrahepatic cholangiocarcinoma. Important upcoming milestone includes topline data from SURF302 expected in 1H 2026.